Lecture in Russian on Breast Cancer - Dr. Nissenbaum
Preview:
DESCRIPTION
Biological Treatments for Breast Cancer
Citation preview
- 1. 25 2010
- 2. ?
- 3.
- 4.
- 5.
- 6. (Targeted therapy)
- 7. -
- 8. , , Tykerb Trastuzumab ErbB3 ErbB2 ErbB1 ErbB2 Pertuzumab
IGF-IR Pazopanib Bevacizumab Ertumaxomab Tanespimycin Alvespimycin
Vorinostat Temsirolimus Everolimus Sunitinib HDAC=histone
deacetylase VEGF PDGFR VEGFR Vascular endothelial cell membrane
PI3K mTOR Akt HSP90 HDAC
- 9.
- 10.
- 11. -
- 12. HER-2
- 13. HER
- 14. HER-2 ,
- 15. ?
- 16. R-2 Herceptin HER-2 , ,
- 17. Herceptin
- 18. Herceptin H R-2
- 19. HERCEPTIN
- 20. HERCEPTIN
- 21. HERCEPTIN , 52% 46% 40%
- 22. Herceptin: 10- Weisgerber-Kriegl et al. ASCO 2008 abstract
6589
- 23. HERCEPTIN HER-2
- - , , ( beyond progression)
- 24. HERCEPTIN HER-2
- 25. R-2 ( Tykerb) HER -2 ,
- 26. - , Ligands HER-2 Other ErbB PI3K/Akt pathway MAPK pathway
(Ras/Raf/ MEK/ERK) PI3K/Akt pathway MAPK pathway (Ras/Raf/
MEK/ERK)
- 27. , ( Tykerb)
- - , HER-2 , HER-2 , Herceptin
- 28.
- 29.
- 30.
- 31.
- 32. ,
- 33. - () ( VEGF) EGF IGF-1 PDGF IL-8 bFGF COX-2 NO VEGF H 2 O 2
P P P P IGF = insulin-like growth factor PDGF = platelet-derived
growth factor
- 34. VEGF -
- 35. ?
- 36. , ( VEGF)
VEGF
- 37. ( VEGF) -
- 38. 1 2 3 1 2 3 1 . Willett et, al. Nat Med 2004; 2 . Baluk, et
al. Curr Opin Genet Dev 2005; 3 . Inai, et al. Am J Pathol 2004; 4
. Gerber, et al. Cancer Res 2005; 5 . Jain. Science 2005
- 39.
- 40.
- 41.
- 42.
- 43.
- 44. HER-2
- 45. TDM1
- 46. PARP
- 47.
- 48. PARP+ BRCA+
- 49.
- BRCA - , ( - triple negative)
- 50. BRCA PARP (1) BRCA PARP++
- 51. BRCA PARP (2) BRCA PARP++
- 52. ?
- 53. PARP
- 54. PARP PARP- BRCA
- 55. PARP
- 56.
- 57.
- 58.
- 59.
- 60.